about
Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8.Prenatal infection and cavum septum pellucidum in adult schizophrenia.Prenatal exposure to maternal infection and executive dysfunction in adult schizophrenia.A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women.Association of maternal genital and reproductive infections with verbal memory and motor deficits in adult schizophreniaComparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study.Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database.Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population.Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal studyLow maternal hemoglobin during pregnancy and diminished neuromotor and neurocognitive performance in offspring with schizophreniaUnderstanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007-2012Neighbourhood variation in the price of soda relative to milk and its association with neighbourhood socio-economic status and race.Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment.Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population.Asthma and Chronic Obstructive Pulmonary Disease Overlap Syndrome: Doubled Costs Compared with Patients with Asthma Alone.Description of cardiovascular event rates in patients initiating chronic opioid therapy for noncancer pain in observational cohort studies in the US, UK, and Germany.Treatment patterns, healthcare utilization, and costs of chronic opioid treatment for non-cancer pain in the United States.Comparative effectiveness of budesonide-formoterol combination and fluticasone-salmeterol combination for asthma management: a United States retrospective database analysis.Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol.Seasonal influenza vaccination trends from 2007-2011 in privately insured children and adults in the United States.Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel IIITreatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care settingOccurrence and Characteristics of Hospitalizations During First-Line Chemotherapy Among Individuals with Metastatic Colorectal CancerThe Association Between Doctor and Pharmacy Shopping and Self-Reported Misuse and Abuse of Prescription Opioids: A Survey StudyTreatment patterns and sequences of pharmacotherapy for patients diagnosed with depression in the United States: 2014 through 2019Medical Conditions Predictive of Self-Reported Poor Health: Retrospective Cohort StudyFrequency of Early Refills for Opioids in the United States
P50
Q30701347-54E1E795-7EE4-403D-91F0-6823EEC73121Q33606379-BC58464B-E331-4326-94AC-2BF77A93312AQ33649386-57768C9D-40EF-4DB6-9D48-03C8A1157B57Q33911131-6759AC19-AA62-4B71-9E69-8B35A6CE967CQ33952707-5BEBEF4B-63BE-4470-8B6F-25BDB91C4B35Q34764361-884BFC8E-5128-4C05-BCBE-B1A38A9DACEFQ35043150-6E033C46-0543-41D7-9439-4A278B54F27CQ35538141-460CD591-650E-46CA-9CAD-9EF112B4E354Q35669486-168B7F8C-FBEA-4428-B594-83EFC5D26CEBQ35892486-03D966A1-B00A-4F8D-8F80-4742814A1D18Q36116549-2C435BCF-C134-4926-B3CF-9D20C3078028Q36526965-4790EBB4-C726-4D79-A472-DEE8079234D0Q36669230-F2FFB122-2BA1-4F9C-9F64-FA43C20C73CFQ36818863-68BFB0C0-319E-434A-AF45-1A7476CD4AD2Q39644495-C6839E9C-834B-4375-B99D-81B291499139Q39898203-74D8DCD7-8B8E-4EF5-A8D2-F8623450F6E2Q40165721-0D9A7F33-5E7B-4132-9081-0D86764F40C0Q40497674-73AF1072-63A4-494E-960D-87E0B0A3DEDFQ43557680-9D226113-9E2F-45BC-A56B-B984EB5D83C3Q44329841-FFC8F0DC-8FE2-4337-82DA-9F13A52566EBQ44944967-90318458-F302-4706-B533-000B0A0037E4Q46006318-6557A24F-1E7F-4382-AA46-4B9CF0CD1874Q51251627-72132EB8-E51C-4562-BE7B-900965002D1CQ85673795-AE4E8E56-B9AF-4159-972E-FB785DCC2ED2Q86064512-D17CDB42-C95E-4240-949C-CF22AAC7203FQ90410265-FD159EB8-9904-4395-9A52-C3CD538AE15CQ92060770-BD434174-4329-4DFC-8AAC-05FA1D9F6FF9Q92404742-71D91500-682B-4D9F-8572-34007A0BB917Q92490412-22C3FD5F-973A-46B1-9DE4-C47DCC4E022CQ96305620-194A0E1D-57DE-4396-89F7-D97B18A1407C
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
David Kern
@ast
David Kern
@en
David Kern
@es
David Kern
@fi
David Kern
@nl
David Kern
@pt
David Kern
@sl
Давид Керн
@ru
دايفيد كيرن
@ar
type
label
David Kern
@ast
David Kern
@en
David Kern
@es
David Kern
@fi
David Kern
@nl
David Kern
@pt
David Kern
@sl
Давид Керн
@ru
دايفيد كيرن
@ar
altLabel
Dave Kern
@en
prefLabel
David Kern
@ast
David Kern
@en
David Kern
@es
David Kern
@fi
David Kern
@nl
David Kern
@pt
David Kern
@sl
Давид Керн
@ru
دايفيد كيرن
@ar
P106
P21
P31
P496
0000-0001-5417-3925